S-4189-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Jeanne Shaheen (D-NH)
What it does
This bill would reduce the price of insulin and establish patient protections related to insulin costs. Because the full bill text has not been published beyond its title and short title, the specific mechanisms — such as price caps, manufacturer requirements, insurance mandates, or subsidy structures — are not yet available for review. The bill was introduced in the Senate on March 25, 2026, and has been referred to the Committee on Health, Education, Labor, and Pensions.
Who benefits
The approximately 8.4 million Americans who use insulin would be the primary intended beneficiaries, particularly those who are uninsured or underinsured and currently face high out-of-pocket costs. Patients who ration insulin doses due to cost — estimated at roughly 1 in 4 insulin users in some surveys — could also benefit. Depending on the specific mechanism, pharmacies, insurers, or employers could benefit if cost-sharing obligations are redistributed.
Who is hurt
Insulin manufacturers (primarily Eli Lilly, Novo Nordisk, and Sanofi) could face reduced revenue if price caps or negotiated price limits are imposed. Pharmacy benefit managers (PBMs) could lose rebate income if the pricing structure changes. Insurers may face higher administrative costs if new coverage mandates are added. Taxpayers could bear costs if the bill includes federal subsidies or Medicaid/Medicare spending increases.
Supporters argue
Supporters argue that insulin list prices in the United States are roughly 10 times higher than in comparable countries, and that this disparity has no clear justification in manufacturing costs. They contend that patients skipping or rationing insulin — a medically necessary drug with no substitute — represents a preventable public health harm, and that federal intervention is warranted when market forces have demonstrably failed to produce affordable access to a life-sustaining medication.
Opponents argue
Opponents argue that government-imposed price limits on insulin could reduce manufacturers' incentives to invest in next-generation insulin formulations and delivery technologies, ultimately harming patients over the long term. They contend that the root cause of high insulin prices is the opaque rebate system involving PBMs and insurers — not manufacturer list prices alone — and that price controls without structural market changes may shift costs rather than eliminate them, potentially raising insurance premiums for all enrollees.
Constitutional context
Congress has broad authority to regulate pharmaceutical pricing through the Commerce Clause (Art. I, §8, cl. 3), as insulin is a product of interstate commerce. If the bill conditions federal Medicaid or Medicare funding on manufacturer compliance, the Spending Clause coercion limits identified in NFIB v. Sebelius (2012) could be relevant. Post-Loper Bright (2024), any agency rules implementing the bill's provisions would face independent judicial review rather than deferential scrutiny.
Checks and balances
Congress would set the pricing or protection framework; HHS and potentially CMS would implement and enforce regulations; manufacturers or insurers could challenge specific provisions in federal court, with judges now exercising independent statutory interpretation under Loper Bright.
Historical precedent
The Inflation Reduction Act of 2022 capped insulin copayments at $35 per month for Medicare Part D enrollees, representing the most recent directly analogous federal action on insulin pricing.